JHL Biotech has opened the new KUBio biopharmaceutical manufacturing facility with single-use bioprocessing technology at in Wuhan, China. JHL will use the KUBio manufacturing solution delivered by GE Healthcare to manufacture biosimilars and monoclonal antibodies (mAbs) for late-stage clinical trials and commercial supply. The facility will also provide process development and manufacturing services for JHL's global customer base. JHL and GE Healthcare partnered to complete the construction of the facility in just 18 months using GE's KUBio manufacturing solution. KUBio is a prefabricated cGMP-compliant facility and process solution designed for scalable and cost-efficient manufacturing. JHL's new facility in Wuhan has the same standardized GE FlexFactory technology as existing site in Taiwan, which allowed to quickly scale up to a capacity of 2,000 litres. JHL Biotech now has the largest volume of single-use cell culture capacity in Asia with the opening of new facility in Wuhan.